Consistently, the down-regulation of Phf2 activity in the liver of NASH patients from the ABOS cohort positively correlates with low liver Nrf2 protein content and the high risk of progression into fibrosis. This evidence concerns the gene NFE2L2 and metabolic dysfunction-associated steatohepatitis.